Vaxcyte, Inc. PCVX Acquired manufacturing rights
Acquired manufacturing rights at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept pcvx:AcquiredManufacturingRightsExpense.
The official record: Vaxcyte, Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s acquired manufacturing rights.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s acquired manufacturing rights?
- Vaxcyte, Inc. (PCVX) reported acquired manufacturing rights of $0 in Q4 2025.
- What is the long-term trend for Vaxcyte, Inc.'s acquired manufacturing rights?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s acquired manufacturing rights has grown at a -100.0% compound annual growth rate (CAGR), from $23M to $0.
- What does acquired manufacturing rights mean?
- This metric represents the costs associated with obtaining the legal or contractual rights to utilize specific manufacturing processes, technologies, or facilities. It reflects the company's strategic investment in securing production capabilities necessary to scale vaccine candidates from development to commercialization. Monitoring this expense helps investors assess the capital intensity of the firm's manufacturing strategy and its progress toward establishing a robust supply chain.